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OPEN
ORIGINAL ARTICLE
Neuroprotection after a ﬁrst episode of mania: a randomized
controlled maintenance trial comparing the effects of lithium
and quetiapine on grey and white matter volume
M Berk1,2,3,4,5,6, O Dandash7,8, R Daglas2,3,10, SM Cotton2,3, K Allott2,3, A Fornito7, C Suo7, P Klauser7,8, B Liberg8,9, L Henry2,3, C Macneil4,
M Hasty4, P McGorry2,3, Cs Pantelis6,8,10 and M Yücel7,10
Lithium and quetiapine are effective treatments for bipolar disorder, but their potential neuroprotective effects in humans remain
unclear. A single blinded equivalence randomized controlled maintenance trial was conducted in a prospective cohort of ﬁrst-
episode mania (FEM) patients (n= 26) to longitudinally compare the putative protective effects of lithium and quetapine on grey
and white matter volume. A healthy control sample was also collected (n= 20). Using structural MRI scans, voxel-wise grey and
white matter volumes at baseline and changes over time in response to treatment were investigated. Patients were assessed at
three time points (baseline, 3 and 12-month follow-up), whereas healthy controls were assessed at two time points (baseline and
12-month follow-up). Patients were randomized to lithium (serum level 0.6 mmol l− 1, n= 20) or quetiapine (ﬂexibly dosed up to
800 mg per day, n= 19) monotherapy. At baseline, compared with healthy control subjects, patients with FEM showed reduced
grey matter in the orbitofrontal cortex, anterior cingulate, inferior frontal gyrus and cerebellum. In addition, patients had reduced
internal capsule white matter volume bilaterally (t1,6643.20, Po0.01). Longitudinally, there was a signiﬁcant treatment × time effect
only in the white matter of the left internal capsule (F2,112 = 8.54, Po0.01). Post hoc testing showed that, compared with baseline,
lithium was more effective than quetiapine in slowing the progression of white matter volume reduction after 12 months
(t1,24 = 3.76, Po0.01). Our data support the role of lithium but not quetiapine therapy in limiting white matter reduction early in the
illness course after FEM.
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INTRODUCTION
Many people with bipolar disorder (BD) manifest a progressive
course. This observation has been repeatedly veriﬁed1,2 and is
manifested by progressively shorter inter-episode intervals,
increasing rates of functional impairment, comorbidity, suicide,
hospitalisation and reduced treatment responsiveness.3–8 More-
over, there are replicated reports of changes over time in brain
volume, suggesting that these neuroanatomical alterations might
be more pronounced with repeated episodes. A larger number of
episodes have been associated with decreased cortical and
subcortical structures including prefrontal and temporal cortices,
the hippocampus and the striatum9–12 accompanied with an
increase in lateral ventricular volume.13–15
The timing of these serial changes in clinical and imaging
variables remains uncertain. What is probable is that people at risk
who later go on to develop BD do not, on aggregate, demonstrate
marked deﬁcits. These appear with the onset of the disorder, and
are evident in an established disease.16 Similarly, structural
changes are inconsistent at a ﬁrst episode, with some studies
showing that individuals at a ﬁrst episode manifest volumetric
ﬁndings similar to controls,17,18 whereas other studies suggest that
changes are already evident.19 Either way, the ﬁrst episode
appears to be the soonest pragmatic point to commence
therapeutic strategies with neuroprotective potential.
A considerable body of evidence from non-randomized studies
suggests that lithium may be associated with preservation or
increase in cortical grey matter20,21 including the prefrontal cortex,22
amygdala and hippocampus.23 Evidence supporting a protective role
for antipsychotics such as quetiapine largely draws on the rather
uncertain schizophrenia literature. While some evidence points to a
protective role for quetiapine that ceases after abstinence,24 other
studies show either an increase only with typical antipsychotics,25
mixed ﬁndings of volumetric increases and reductions 26 or dose-
dependent effects.27 A naturalistic study that examined longitudinal
changes in grey and white matter in a cohort of schizophrenia and
BD patients, treated with second-generation antipsychotics including
quetiapine, found a signiﬁcant reduction in the frontal cortex in the
schizophrenia group and no change in the BD group.17
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Despite the considerable evidence that atypical agents have
clinical utility in BD, there is a lack of randomised controlled trials
with imaging endpoints focusing on volumetric changes in
response to treatment. To examine which agent may have better
neuroprotective properties, a cohort of individuals were studied
who had been stabilized after a ﬁrst episode of mania on a
combination of lithium and quetiapine and then randomized to
either lithium or quetiapine monotherapy. Voxel-based morpho-
metry was utilised to determine white and grey matter volume
changes at baseline and at 3 and 12 months in treatment groups
in comparison with healthy controls. We hypothesised that ﬁrst-
episode mania (FEM) patients would show altered brain volume
compared with control subjects at baseline and that lithium and
quetiapine treatments would be equivalent in affecting changes in
brain volume in the ﬁrst year following a ﬁrst episode of mania.
MATERIALS AND METHODS
Study design
A single-blind controlled randomised parallel group design was conducted
over 52 weeks at two sites in Melbourne, Australia; Orygen, The National
Centre of Excellence in Youth Mental Health, the Early in Life Mental Health
Service and the Recovery and Prevention of Psychosis services at Monash
Health. In this trial, all individuals presenting with an acute ﬁrst episode of
mania with psychotic features were stabilised on a combination of
quetiapine plus lithium in an open manner as part of a routine care
protocol. Following the provision of informed consent, patients were
randomised after remission (a period of between 2 and 3 months) to either
lithium or quetiapine monotherapy. The study was conducted according to
the Good Clinical Practice guidelines and was approved by all relevant
ethical committees.
Participants
Patients meeting Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition, Text Revision (DSM-IV-TR) criteria for a manic episode on the
Structured Clinical Interview for DSM-IV-TR—Patient Edition (SCID-I/P)28
were recruited between December 2008 through December 2013.
Individuals with a ﬁrst-episode illness of bipolar I disorder, substance-
induced mood disorder or schizoaffective disorder and aged 15–25 years
were included. Other inclusion criteria included: a Young Mania Rating
Scale (YMRS) score of at least 20 for the acute phase of a ﬁrst episode of
mania; no previously treated manic episode(s); capacity to provide
informed consent to the study and comply with study procedures; be
utilising effective contraception if female and to have been on quetiapine
and lithium as standard therapy for at least 1 month before randomisation.
Exclusion criteria from the trial included: patients with a known or
suspected clinically relevant systemic medical disorder; pregnant or
lactating females; patients who had a prior sensitivity or allergy to
quetiapine, lithium or their components; inability to comply with either the
requirements of informed consent or the treatment protocol; non-ﬂuency
in English; history of epilepsy; clinically relevant biochemical or haemato-
logical abnormalities at baseline; patients at immediate risk of self-harm or
risk to others; organic mental disease, including mental retardation (full-
scale intelligence quotient o70); and an absolute neutrophil count of
⩽ 1.5 × 109 l− 1. Use of cytochrome P450 3A4 inhibitors in the 14 days
preceding enrolment was not permitted including ketoconazole, itracona-
zole, ﬂuconazole, erythromycin, clarithromycin, troleandomycin, indinavir,
nelﬁnavir, ritonavir, ﬂuvoxamine and saquinavir. Similarly, the use of
cytochrome P450 inducers was not permitted in the 14 days preceding
enrolment including phenytoin, carbamazepine, barbiturates, rifampacin,
St John’s Wort or glucocorticoids. Extra exclusion criteria applied to
individuals with diabetes mellitus (DM): unstable DM deﬁned as enrolment
glycosylated haemoglobin (HbA1c) 48.5; admission to hospital for
treatment of DM or DM-related illness in the previous 12 weeks; not
under physician care for DM; physician responsible for patient’s DM care
did not indicate that patient’s DM was controlled; physician responsible for
patient’s DM care did not approve patient’s participation in the study; had
not been on the same dose of oral hypoglycaemic drug(s) for the 4 weeks
before randomisation (8 weeks for thiazolidinediones); and daily insulin
had been more than 10% outside their mean monthly dose on one or
more occasions in the preceding 4 weeks.
All individuals presenting with an acute ﬁrst manic episode with
psychotic features were acutely stabilised on a combination of quetiapine
plus lithium in an open manner as part of a routine care protocol.
Individuals received quetiapine at a dose determined by the treating
clinician. Optimal serum lithium levels targeted in the acute phase were
between 0.8 and 1.0 mmol l− 1. Following clinical stabilisation (based on
the global impression of the treating clinician or team), subjects were
randomised to either quetiapine or lithium. Lithium levels of 0.6–
0.8 mmol l− 1 were targeted in the maintenance phase, and the quetiapine
dose was determined by the treating clinician (up to 800 mg per day).
Randomisation and blinding
At the discretion of the treating team, an independent statistician
generated a computerised randomisation sequence 2–3 months following
stabilisation from a FEM. A randomisation log was established and a set of
sequentially ordered envelopes was kept in a locked ﬁling cabinet at the
Orygen Research Centre site. Care was taken to maintain the single-blind
nature of the study; patients and clinical staff including treating
psychiatrist and case managers knew which treatment the patient was
receiving while research staff including research assistants, neuropsychol-
ogists and all individuals involved in neuroimaging, analysis and data
management remained blinded to this information. Participants were
instructed not to communicate information regarding treatment to the
research assistants and imaging personnel by the study clinicians, and no
information regarding treatment was communicated at team meetings or
was included in the study ﬁles to which the research assistants had access.
Procedure
Clinical assessments were carried out at baseline and on fortnightly
intervals for the ﬁrst month, then on a monthly basis for the following two
months and then at three monthly intervals thereafter concluding at the
12-month time point. The clinical assessment included observer-based
ratings using the YMRS for manic symptoms, the Montgomery-Åsberg
Depression Rating Scale29 for depressive symptoms; the Brief Psychiatric
Rating Scale30 for overall psychopathology and severity of psychotic
symptoms; and the Clinical Global Impression scale for use in BD31 to
determine overall symptom severity. Control subjects underwent MRI
scanning at baseline and at the 12-month time points, whereas FEM
patients were scanned at baseline, 3 and 12-month time points to better
assess response to treatment.
MRI data acquisition
3 T Siemens Trio Tim scanner (32 channel head coil) at the Murdoch
Children’s Research Institute in Melbourne, Australia, was used to acquire
high-resolution structural T1 Magnetisation-Prepared RApid Gradient-Echo
(MPRAGE32) scans for each subject. Image acquisition parameters at
every time point were as follows: 192 sagittal slices with a nominal 1 mm3
voxel size, 256 mm×232 mm ﬁeld-of-view and a matrix size of 256× 192
pixel resolution, 2000 ms repetition time and 2.24 ms echo time. Structural
images of 25 patients were sampled at twice the resolution resulting
in a matrix size of 512× 384 pixels and an in-plane resolution of
0.5 mm×0.5 mm.
Voxel-based morphometry (pre-processing)
Pre-processing and post-processing for baseline and longitudinal compar-
isons were carried out in the VBM8 toolbox implemented in Statistical
Parametric Mapping (SPM8; http://www.ﬁl.ion.ucl.ac.uk/spm/software/
spm8/) running in Matlab v.8.1 (MathWorks, Matick, MA, USA). Structural
images were routinely inspected for artifacts and gross abnormalities. For
baseline comparison voxel-wise analyses of brain gray matter volume and
white matter volume differences were conducted using the Diffeomorphic
Anatomical Registration Through Exponentiated Lie Algebra (DARTEL33).
Brieﬂy, each participant’s T1-weighted anatomical scan was segmented
into distinct tissue compartments and spatially normalised. A study-
speciﬁc template was generated by normalising each participant’s
segmented grey or white matter image to a common space. Native-
space grey or white matter images were then spatially normalised to this
template. Modulation (nonlinear only) normalisation was used to preserve
the amount of grey and white matter. The resulting modulated and
spatially normalised segments were then smoothed with a 6.0 mm full
width at half maximum spatial smoothing kernel in order to minimise
anatomical residuals from registration. Grey and white matter segments
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were checked for segmentation and normalisation artifacts. Intracranial
volume was calculated from the raw anatomical images in the subject’s
native space as the total volume of grey matter, white matter
and cerebrospinal ﬂuid.
For longitudinal comparison, the VBM8 longitudinal pipeline was used.
Brieﬂy, for each subject, after follow-up images were initially realigned to
baseline, a mean image was created and used as a reference image to which
baseline and longitudinal images were realigned again. The realigned
images at each time point were then corrected for signal inhomogeneity
(bias correction) and segmented. Spatial normalisation using DARTEL was
applied to the reference image, after which normalisation parameters were
applied to the realigned and bias-corrected segments.
Statistical analyses
Baseline differences in grey and white matter volume between FEM
patients (collapsed across treatment groups) and control subjects were
tested using the General Linear Model as implemented in the FSL feature
Randomise (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Randomise). All results were
corrected for type I error with a nonparametric threshold-free cluster
enhancement procedure employing 1000 permutations.34 Age and gender
were included as covariates of no interest. Results were considered
signiﬁcant if they passed a threshold Po0.01. The results were then saved
to mask treatment × time interaction results, thus ensuring that treatment
effects were investigated in brain regions of primary pathophysiological
importance to BD.
To examine changes in grey and white matter volume in response to
treatment over time, preprocessed whole-brain grey and white matter
segments were entered into separate ﬂexible factorial models with group
(control, quetiapine and lithium) and time (baseline, 3 months and
12 months) as factors and age, gender, DSM-IV-TR diagnosis (see
Supplementary Table 1 for more information) and psychotropic medica-
tion as covariates of interest. In this analysis the effect of lithium versus
quetiapine treatment on longitudinal changes in baseline differences in
grey and white matter (treatment × time interaction) was the outcome
measure. Group× time interactions were modelled using an F-test masked
with the between-group difference results generated at baseline.
Interaction results were corrected for multiple comparisons using small-
volume correction as implemented in SPM8 with the between-group
difference results mask generated at baseline as the volume of interest.
Results that survived a threshold of Po0.01 were considered signiﬁcant. A
group× time interaction plot was generated by extracting the ﬁrst
eigenvariates (weighted averages) of white matter volume estimates from
clusters that survived correction for multiple comparisons (Figure 1). Three
months' follow-up data were compared separately for treatment groups
exclusive of control data. Three months' follow-up data for control subjects
were estimated by linear interpolation of baseline and 12 months data
points and included for presentation purposes only.
RESULTS
Of the 61 recruited subjects, 11 in the quetiapine treatment group
and 9 in the lithium treatment group were excluded at or before
randomisation took place for the following reasons: relapse at
baseline or before commencement of monotherapy (n= 5); self-
ceasing of all medications (n= 3); non-stability on monotherapy
(n= 2); preference for the non-randomized medication (n= 3);
clinician withdrawal due to side effects (n= 2); and treatment
disengagement (n= 4). Twenty-one patients were allocated to
quetiapine treatment and 20 subjects were allocated to lithium.
Two additional subjects were excluded at baseline; one subject
because of never being on monotherapy and one subject because
of non-compliance to randomized medication, rendering a ﬁnal
sample of 19 subjects in the quetiapine group and 20 subjects in
the lithium group. Three patients in the quetiapine group and
four in the lithium group discontinued after their baseline
participation.
Treatment groups were matched for age, gender, handedness
and intelligence quotient, but only matched for age and
handedness with the control group (Table 1). Treatment groups
(lithium and quetiapine) clinical scores did not differ across all
clinical scales at baseline, indicating that stabilisation was
successful (Table 1).
FEM patients (collapsed across treatment groups) demonstrated
reduced regional grey and white matter volume compared with
control subjects at baseline (Po0.01 corrected; Figure 1 and
Table 2). Speciﬁcally, patients showed reduced grey matter
volume in the orbitofrontal cortex, anterior cingulate cortex and
the inferior frontal gyrus, as well as in the cerebellum (Figure 1 and
Table 2). In addition, patients had reduced internal capsule white
matter volume bilaterally (Figure 1 and Table 2). These ﬁndings
clarify brain areas affected in participants stabilized in the
aftermath of a FEM, and before monotherapy was commenced.
Longitudinally, there was a signiﬁcant treatment × time effect
only in the white matter of the left internal capsule (F2,112 = 10.44,
Po0.01; Table 2 and Figure 2). To further assess whether the
treatment effect exceeds the test–retest variability in control
subjects, we assessed treatment × time interaction for each of the
treatment group separately with the control group. We found no
group× time interaction effect for the lithium group when
compared with healthy control subjects and only in the
quetiapine group (F = 12.32, Po0.01 corrected). Post hoc testing
showed that lithium was more effective than quetiapine in
slowing the progression of white matter volume reduction as
suggested by the difference score in white matter estimates
between baseline and 12 months only (t1,24 = 3.76, Po0.01;
Figure 2) but not after 3 months (t1,27 = 1.3, P= 0.21). There were
no other reductions or increases in grey or white matter volumes
over time across any of the groups.
DISCUSSION
To the best of our knowledge, this is the ﬁrst longitudinal
structural neuroimaging study to characterize the neuroprotective
effects of lithium and quetiapine in participants following a FEM.
Compared with healthy controls, FEM patients demonstrated
reduction in brain volume in a number of previously identiﬁed
areas,12,35,36 including the orbitofrontal cortex, anterior cingulate
cortex, inferior frontal gyrus and cerebellum at baseline.
Volumetric reductions in white matter were restricted to the
internal capsule bilaterally. Furthermore, we assessed differences
in the effect of treatment across three time points, which has not
previously been done. We found a signiﬁcant effect of treatment
on white matter, with the lithium group showing an attenuated
reduction of white matter volume over time compared with the
quetiapine group at 12 months of follow-up.
At baseline, we identiﬁed between-group differences conﬁned
to structures widely implicated in BD.37 We did not identify any
regional changes in disease-speciﬁc grey matter across groups
over time, and this absence of change is corroborated by another
longitudinal study of FEM patients with BD.38 However, there are
Figure 1. Z-score statistical map of reduced grey matter (left inset)
and white matter (right inset) volume in ﬁrst-episode mania patients
(N= 39) when compared with healthy control subjects (N= 30) at
baseline. Right hemisphere is shown on the right. Numbers
represent MNI coordinates in each corresponding plane. Results
are threshold-free cluster-enhancement-corrected for multiple
comparison (PTFCEo0.01). See Table 2 for more information. MNI,
Montreal Neurological Institute.
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structural neuroimaging ﬁndings that suggest a progressive grey
matter loss in the prefrontal cortex and anterior cingulate cortex in
BD.39 The absence of grey matter alterations over time may be a
result of a neuroprotective effect of medications or due to
common neuropathology limited to psychotic illnesses that
differentiates after ﬁrst episode of mania.38,40 This notion is
supported by ﬁnding that progressive loss of grey matter in both
the cingulate cortex and the cerebellum have been shown to be
speciﬁc to subjects who later on developed psychosis.41
The superiority of lithium on white, but not grey, matter
outcomes contrasts with previous ﬁndings.12,35 Demonstrating an
increased volume in the anterior cingulate cortex,12 hippocampus
and amygdala42 was associated with lithium treatment in BD
patients. Nonetheless, our ﬁnding of no change in grey matter
over time is in agreement with a number of other studies that
found either no change in grey matter volume43 or more
extensive changes in white matter volume only.38,40 The
discrepancy in these ﬁndings can be attributed to the relatively
lower incidence of multiple episodes and hence abnormalities
severity in this sample compared with other studies15 and the
relative age of participants.44
Although reduced white matter in the internal capsule volume
was detected bilaterally at baseline, we detected a treatment
effect only in the left hemisphere. This result may suggest that left
Table 2. Brain regions demonstrating baseline differences as well as group× time interaction effect in grey and white matter volume between ﬁrst-
episode mania patients and control subjects
Baseline comparison Hemisphere Peak MNI coordinates (x,y,z) Cluster size voxels (mm3) z-score
Grey Matter
Orbitofrontal cortex/gyrus rectus Right − 3, 38, − 27 170 (574) 4.56
Cerebellum Left − 30, − 66, − 21 1190 (4016) 5.12
Cerebellum Right 39, − 63, − 22 1755 (5923) 5.07
White matter
Internal capsule Right 20, − 18, 2 336 (1134) 5.29
Internal capsule Left − 22, -19, -6 171 (577) 5.37
Group× time interaction (white matter)
Internal capsule Left − 22, − 19, −8 82 (277) 3.64
Abbreviation: MNI, Montreal Neurological Institute. Results are corrected for multiple comparison (Po0.01).
Table 1. Demographic and clinical characteristics of FEM patients and healthy control subjects
Demographics Control N= 30 Quetiapine (N=19) Lithium (N=20) Statistics
N % N % N % χ2 P
Gender
Male 12 40 14 70 16 84 9.87 0.007
Female 18 60 5 30 4 16
Handednessa
Right-handed 26 93 15 83 19 95 3.64 0.162
Left-handed 2 7 3 17 0 0
Age Mean s.d. Mean s.d. Mean s.d. F
21.40 2.46 21.47 2.14 21.45 2.31 0.145 0.88
Premorbid IQ (WTAR) 105.43 10.82 92.89 13.80 96.71 13.89 11.37 0.001
Baseline clinical scoresb (total) Control Quetiapine Lithium Statistics
Mean s.d. Mean s.d. Mean s.d. Mann–Whitney Z P
YMRS — — 1.86 2.21 2.85 4.4 − 0.074 0.941
MADRS — — 7.05 8.63 7.05 9.09 − 0.667 0.505
CGI-BP (Severity of overall bipolar) — — 1.89 1.52 2.10 1.48 − 0.677 0.498
CGI-BP (Severity of mania) — — 1.00 0.00 1.20 0.70 − 1.396 0.163
CGI-BP (Severity of depression) — — 2.00 1.49 2.10 1.71 − 0.047 0.962
BPRS — — 32.47 8.42 33.80 10.19 − 0.297 0.767
Abbreviations: BPRS, Brief Psychiatric Rating Scale; CGI-BP, Clinical Global Impressions scale for use in bipolar disorder; FEM, ﬁrst-episode mania; IQ, intelligence
quotient; MADRS, Montgomery Asperger Depressive Rating Scale; WTAR, Wechsler Test of Adult Reading (UK-scaled score); YMRS, Young Mania Rating Scale.
aData for two subjects in the control group and one subject in the quetiapine and the lithium group were missing . bFollow-up data for four and seven
subjects were missing from the quetiapine and lithium group, respectively.
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white matter volume is more susceptible to illness processes in
FEM patients in this brain region. This notion is in agreement with
previous ﬁndings, showing a longitudinal reduction in white
matter volume to be more affected in the left hemisphere (6.5%)
in bipolar patients when compared with baseline.45 Furthermore,
structural imaging studies investigating aspects of water diffusion
in white matter ﬁbre tracts have shown reduced fractional
anisotropy in the left internal capsule only46 and loss of the
normal left-sided symmetry in the posterior limb of the internal
capsule,47 suggesting speciﬁc microstructural abnormality to the
left hemisphere.
The duration of lithium treatment in this study is worth
considering as it points to an effective cessation of white matter
loss during the ﬁrst 3 months and a subsequent normalisation of
this effect to similar rate to that expected in control subjects
(Figure 2). Previous studies demonstrated that among people with
BD those with a greater duration of treatment with lithium
manifested better adjusted white matter48 as well as grey matter
integrity.49 In addition, there are preliminary reports of associa-
tions between white matter hyperintensities and better lithium
response.50 These ﬁndings strongly suggest that lithium has a role
in myelin physiology. In a crush injury model, for example, lithium
is shown to enhance the re-myelination of peripheral nerves.51 An
operative pathway whereby lithium acts on white matter seems to
be via glycogen synthase kinase 3-β.52 The mechanism involves
regulation of the genes for myelin basic protein and proteolipid
protein expression in mouse oligodendrocytes.53
The results of this study do not support a neuroprotective role
for quetiapine nor do they support a neurotoxic effect. This is
clearly demonstrated by the fact that treatment groups did not
differ on measures of both grey and white matter at baseline or in
grey matter longitudinally. Rather, quetiapine seems to take much
longer to exert an effect on white matter, suggesting perhaps a
slower and less potent effect than lithium. Despite being a
multisite study conducted over 5 years, the sample size of this
study was limited. This is driven by the low incidence of FEM,
together with the requirement to have been treated and stabilized
on a combination of lithium and quetiapine, and to then agree to
randomisation, be happy with the randomized agent and the trial
assessments. As expected, there was a group of individuals who
did not complete the trial, decreasing power at the ﬁnal
time point.
White matter neuroimaging metrics that reﬂect axonal struc-
ture, such as fractional anisotropy, and the mean and radial
diffusivity are altered in people with BD compared with controls.54
Alterations in white matter microarchitecture have also been
shown to be associated with poorer treatment response.55 This
suggests that there is a process of disturbed myelination in the
disorder that is seemingly not associated with axonal loss.56 Such
changes can only be assessed with diffusion imaging that may
prove more sensitive to axonal pathology than voxel-based
morphometry analysis.
That most patients had psychotic symptoms at baseline means
that these data cannot be extrapolated to non-psychotic
individuals. The cohort included individuals with bipolar and
schizoaffective disorder, although only a small number of
participants had the latter diagnosis. Data regarding quetiapine
cannot be extrapolated to other antipsychotics. To make the trial
feasible, concomitant medications were allowed, and their role
cannot be excluded. Dropout rates of around a third are not
unexpected in a ﬁrst-episode population, and the results need to
be interpreted cognizant of this characteristic. Similarly, there was
an imbalance between patients and controls regarding intelli-
gence quotient and gender, which is a limitation. High rates of
substance use in the cohort may have inﬂuenced the results,
although both treatment groups were matched for subjects with
substance/alcohol abuse and hence the results are not likely to be
attributed to their effect. Because substance abuse is very
common in this population, it was allowed to enhance general-
isation. The randomized design, the two post-baseline scans using
a single scanner and the 1-year follow-up are strengths of the
design.
In summary, the data support the role of lithium in preventing
white matter changes after a ﬁrst episode of mania. In addition,
given the progressive nature of the disorder, and the lack of data
showing that established cognitive or imaging changes could be
reversed, these data support the continuing use of lithium from
the earliest stages of the disorder, pragmatically translated as the
ﬁrst episode. They thus challenge earlier guidelines, suggesting
that one might wait for the passage of several episodes before
commencing lithium.57–61
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Figure 2. Time plot of signiﬁcant changes in white matter volume
over time in the left internal capsule (inset). Asterisk: signiﬁcant
between treatment group differences corrected (PSMVo0.01); error
bars represent s.d. See Results section, Table 2 and Supplementary
Materials for more information.
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